| Project/Area Number |
26290052
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
Kawakami Koji 京都大学, 医学(系)研究科(研究院), 教授 (70422318)
|
|---|
| Research Collaborator |
HORIBE TOMOHISA 京都大学, 大学院医学研究科, 特定准教授 (20467468)
KOHNO MASAYUKI 京都大学, 大学院医学研究科, 特定講師 (00437203)
KURIHARA RYOUSUKE 青山学院大学, 化学・生命科学科, 助教 (20713233)
SETO KAHORI 京都大学, 大学院医学研究科, 特定助教 (20737019)
ARONGGAOWA 三重大学, 大学院医学系研究科, 助教 (50643805)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2016: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Keywords | 分子標的治療 / ペプチド創薬 / ハイブリッドペプチド / 難治性癌 |
|---|
| Outline of Final Research Achievements |
We focused on the IL-13 receptor alpha 2 (IL13Ralpha2), which plays critical and important roles in glioblastoma cells, and performed the screening binding peptide to the receptor using T7 phage display system. We successfully selected one candidate peptide binding specifically to IL13Ralpha2, and designed IL13Ra2-lytic hybrid peptide by conjugation with lytic type peptide against cancer membrane. It was found that IL13Ra2-lytic had effective cytotoxic activity against glioblastoma cell lines which express IL13Ralpha2, and the peptide had also anti-tumor activity in vivo. These results suggest that hybrid peptide designed in this study may also new candidate for the development of glioblastoma treatment in the future.
|
